| pubmed-article:18405948 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C0332325 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C1516155 | lld:lifeskim |
| pubmed-article:18405948 | lifeskim:mentions | umls-concept:C0762739 | lld:lifeskim |
| pubmed-article:18405948 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18405948 | pubmed:dateCreated | 2008-6-6 | lld:pubmed |
| pubmed-article:18405948 | pubmed:abstractText | To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer. | lld:pubmed |
| pubmed-article:18405948 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18405948 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18405948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405948 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18405948 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:18405948 | pubmed:issn | 1095-6859 | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:LeeKyung-HeeK... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:BangYung-JueY... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:SongYong... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:KimJong-Hyeok... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:LeeHyo-PyoHP | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:SeoSang-SooSS | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:RyuSang-Young... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:KangSoon-Beom... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:ParkSang-Yoon... | lld:pubmed |
| pubmed-article:18405948 | pubmed:author | pubmed-author:NamJoo-HyunJH | lld:pubmed |
| pubmed-article:18405948 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18405948 | pubmed:volume | 109 | lld:pubmed |
| pubmed-article:18405948 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18405948 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18405948 | pubmed:pagination | 359-63 | lld:pubmed |
| pubmed-article:18405948 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:meshHeading | pubmed-meshheading:18405948... | lld:pubmed |
| pubmed-article:18405948 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18405948 | pubmed:articleTitle | Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. | lld:pubmed |
| pubmed-article:18405948 | pubmed:affiliation | Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul 110-744, Korea. | lld:pubmed |
| pubmed-article:18405948 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18405948 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18405948 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
